ASCO
2010 Presentation
Highlights and video from the poster
presentation made at ASCO 2010
Provectus
Updates Shareholders on 2009 Year-to-date Accomplishments
Progress Made In Therapies for Metastatic
Melanoma, Atopic Dermatitis and Psoriasis
ASCO
2009 Presentation
Highlights and video from the poster
presentation made at ASCO 2009
6th
International Symposium on Melanoma and Other Cutaneous Malignancies
Professor John F. Thompson,M.D. presentated
interim results of the phase 2 clinical trial of PV-10 for melanoma in
March 2009.
Perspectives
In Melanoma Conference XII Presentation
Professor John F. Thompson,M.D. presented
interim results of Phase 2 PV-10 for melanoma trial in October 2008.
PV-10
for Melanoma Story Airs in Australia
Video interviews with Professor John
Thompson and a patient who was involved in the Phase 2 study of PV-10
for melanoma.
SCC
2008 Presentation
Professor John Thompson of the Sydney
Melanoma Unit presents preliminary findings from Phase 2 study of PV-10
for melanoma.
Provectus
Preview
30 second preview of Provectus' multimedia
annual report.
Clinical trial information at ClinicalTrials.gov
Summary of the clinical effects of PV-10 on melanoma
Melanoma Research Publishes PV-10 Article
[video] PV-10 for melanoma story airs on Australian TV
Information on the Compassionate Use Program for PV-10
Opening
a New Front in the
War Against Cancer
Provectus Pharmaceuticals is developing advanced therapies designed to:
Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.
For further information, read our detailed Research Reports.
Legal Notice ©2002-2012 Provectus Pharmaceuticals, Inc.
Provectus's cancer drug PV-10 (Rose Bengal) was discussed in a December 20, 2011 article titled "Catastrophic Success" appearing in John Mauldin's Out of the Box newsletter.
Provectus CEO Craig Dees, PhD will be presenting at the New York Society of Security Analysts' 15th Annual Biotech and Specialty Pharmaceuticals Conference on November 30, 2011 in New York City.
Two recent articles in the Journal of Surgical Oncology give very positive reports on PV-10 for metastatic melanoma.
An article appearing in the September 2011 edition of Cancer Watch discusses the recent rise in interest in using intralesional therapies for treating metastatic melanoma.
Medical News Today published two articles on September 29th covering PV-10 for melanoma and liver cancer.
Pharmacy and Therapeutics highlights intralesional therapies, including Rose Bengal (PV-10), in its coverage of the inaugural "HemOnc Today: Melanoma and Cutaneous Malignancies" meeting.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) has received guidance from the U.S. Food and Drug Administration ("FDA") to submit its Phase 3 protocol for review, either via standard review or a request for Special Protocol Assessment ("SPA"). This guidance was in response to Provectus's request of a final end-of-Phase 2 meeting to achieve consensus on design of a planned pivotal Phase 3 randomized controlled trial ("RCT") of PV-10 for metastatic melanoma.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announces that nonclinical data on the immunologic mechanism of action of PV-10 will be presented at the Society of Surgical Oncology Annual Meeting, March 21-24, 2012, at the Orlando World Center Marriott in Orlando, Florida.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announced today that Craig Dees, Ph.D., CEO, will present at BOCEMb: Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18, 2012 at 1:00 PM EST.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announced today that it and its five wholly owned subsidiaries, Pure-ific Corporation, Provectus Biotech, Inc., Provectus Devicetech, Inc., Provectus Imaging, Inc., and Xantech Pharmaceuticals, Inc. (the "Subsidiaries"), have completed an unregistered offering of Units pursuant to the exemption from registration requirements under Rule 506 of Regulation D and Section 4(2) of the Securities Act of 1933.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) has held its third end-of-Phase 2 meeting with the U.S. Food and Drug Administration ("FDA"). The meeting, held October 18, 2011, addressed several topics central to definition of the applicable patient population and primary endpoint for the Company's planned pivotal Phase 3 randomized controlled trial ("RCT") of PV-10 for metastatic melanoma.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.